S&P 500   4,596.49 (+0.65%)
DOW   34,599.63 (+0.34%)
QQQ   393.43 (-0.10%)
AAPL   167.34 (+1.23%)
MSFT   334.55 (+1.20%)
FB   316.93 (-2.32%)
GOOGL   2,867.44 (+1.04%)
AMZN   3,479.00 (-0.80%)
TSLA   1,123.31 (-1.87%)
NVDA   320.94 (-1.78%)
BABA   123.83 (-2.90%)
NIO   39.20 (+0.18%)
CGC   10.20 (-4.76%)
AMD   151.71 (-4.21%)
GE   94.69 (-0.32%)
MU   86.75 (+3.27%)
T   22.40 (-1.88%)
F   20.06 (+4.53%)
DIS   143.92 (-0.68%)
PFE   54.86 (+2.10%)
ACB   6.11 (-4.83%)
AMC   30.63 (-9.75%)
BA   192.12 (-2.90%)
S&P 500   4,596.49 (+0.65%)
DOW   34,599.63 (+0.34%)
QQQ   393.43 (-0.10%)
AAPL   167.34 (+1.23%)
MSFT   334.55 (+1.20%)
FB   316.93 (-2.32%)
GOOGL   2,867.44 (+1.04%)
AMZN   3,479.00 (-0.80%)
TSLA   1,123.31 (-1.87%)
NVDA   320.94 (-1.78%)
BABA   123.83 (-2.90%)
NIO   39.20 (+0.18%)
CGC   10.20 (-4.76%)
AMD   151.71 (-4.21%)
GE   94.69 (-0.32%)
MU   86.75 (+3.27%)
T   22.40 (-1.88%)
F   20.06 (+4.53%)
DIS   143.92 (-0.68%)
PFE   54.86 (+2.10%)
ACB   6.11 (-4.83%)
AMC   30.63 (-9.75%)
BA   192.12 (-2.90%)
S&P 500   4,596.49 (+0.65%)
DOW   34,599.63 (+0.34%)
QQQ   393.43 (-0.10%)
AAPL   167.34 (+1.23%)
MSFT   334.55 (+1.20%)
FB   316.93 (-2.32%)
GOOGL   2,867.44 (+1.04%)
AMZN   3,479.00 (-0.80%)
TSLA   1,123.31 (-1.87%)
NVDA   320.94 (-1.78%)
BABA   123.83 (-2.90%)
NIO   39.20 (+0.18%)
CGC   10.20 (-4.76%)
AMD   151.71 (-4.21%)
GE   94.69 (-0.32%)
MU   86.75 (+3.27%)
T   22.40 (-1.88%)
F   20.06 (+4.53%)
DIS   143.92 (-0.68%)
PFE   54.86 (+2.10%)
ACB   6.11 (-4.83%)
AMC   30.63 (-9.75%)
BA   192.12 (-2.90%)
S&P 500   4,596.49 (+0.65%)
DOW   34,599.63 (+0.34%)
QQQ   393.43 (-0.10%)
AAPL   167.34 (+1.23%)
MSFT   334.55 (+1.20%)
FB   316.93 (-2.32%)
GOOGL   2,867.44 (+1.04%)
AMZN   3,479.00 (-0.80%)
TSLA   1,123.31 (-1.87%)
NVDA   320.94 (-1.78%)
BABA   123.83 (-2.90%)
NIO   39.20 (+0.18%)
CGC   10.20 (-4.76%)
AMD   151.71 (-4.21%)
GE   94.69 (-0.32%)
MU   86.75 (+3.27%)
T   22.40 (-1.88%)
F   20.06 (+4.53%)
DIS   143.92 (-0.68%)
PFE   54.86 (+2.10%)
ACB   6.11 (-4.83%)
AMC   30.63 (-9.75%)
BA   192.12 (-2.90%)
NASDAQ:CLDX

Celldex Therapeutics News Headlines

$37.22
-0.88 (-2.31%)
(As of 12/1/2021 02:20 PM ET)
Add
Compare
Today's Range
$37.09
$39.65
50-Day Range
$38.10
$56.27
52-Week Range
$15.37
$57.20
Volume
10,860 shs
Average Volume
644,942 shs
Market Capitalization
$1.74 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.74

Media Mentions By Week



Celldex Therapeutics Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CLDX
News Sentiment

0.50

0.30

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CLDX Articles
This Week

1

1

CLDX Articles
Average Week

Get Celldex Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CLDX and its competitors with MarketBeat's FREE daily newsletter.

Celldex Therapeutics (NASDAQ:CLDX) News Headlines Today

SourceHeadline
nasdaq.com logoNotable Two Hundred Day Moving Average Cross - CLDX
nasdaq.com - November 30 at 2:24 PM
MarketBeat logoCelldex Therapeutics (NASDAQ:CLDX) Trading Up 4.7%
americanbankingnews.com - November 15 at 12:44 PM
finance.yahoo.com logoCelldex Presents Positive Preclinical Data from PD-1/ILT4 Bispecific Antibody Program CDX-585 at SITC 2021
finance.yahoo.com - November 12 at 11:20 AM
benzinga.com logoCelldex to Participate in Upcoming Investor Conferences
benzinga.com - November 11 at 7:06 AM
MarketBeat logoCelldex Therapeutics (NASDAQ:CLDX) Announces Earnings Results
americanbankingnews.com - November 10 at 3:50 PM
finance.yahoo.com logoCelldex Therapeutics (CLDX) Reports Q3 Loss, Lags Revenue Estimates
finance.yahoo.com - November 9 at 11:44 PM
finance.yahoo.com logoCelldex Reports Third Quarter 2021 Financial Results and Provides Corporate Update
finance.yahoo.com - November 9 at 6:44 PM
finance.yahoo.com logoCelldex Therapeutics (CLDX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
finance.yahoo.com - October 28 at 6:49 PM
finance.yahoo.com logoShould I Avoid Celldex Therapeutics, Inc. (CLDX)?
finance.yahoo.com - October 25 at 2:09 PM
nasdaq.com logoCelldex Therapeutics is Now Oversold (CLDX)
nasdaq.com - October 19 at 12:10 AM
nasdaq.com logoFirst Week of December 17th Options Trading For Celldex Therapeutics (CLDX)
nasdaq.com - October 15 at 8:09 PM
finance.yahoo.com logoCLDX Oct 2021 60.000 put
finance.yahoo.com - October 1 at 3:53 PM
finance.yahoo.com logoCLDX Oct 2021 45.000 call
finance.yahoo.com - September 29 at 1:50 AM
finance.yahoo.com logoCelldex Presents Positive Data on Symptom Control and Quality of Life Measurements that Further Support CDX-0159 Clinical Benefit in Phase 1b Study in Chronic Inducible Urticaria at EADV 2021
finance.yahoo.com - September 29 at 1:50 AM
finance.yahoo.com logoCelldex to Present at the 2021 Cantor Virtual Global Healthcare Conference
finance.yahoo.com - September 24 at 9:30 AM
finance.yahoo.com logoCelldex Announces Upcoming Presentation of CDX-0159 Phase 1b Results in Inducible Urticaria at the 2021 European Academy of Dermatology and Venereology (EADV) 30th Congress
finance.yahoo.com - September 23 at 9:27 AM
finance.yahoo.com logoInvestors in Celldex Therapeutics (NASDAQ:CLDX) have made a enviable return of 729% over the past three years
finance.yahoo.com - September 16 at 8:54 AM
finance.yahoo.com logoCelldex (CLDX) Initiates Subcutaneous Skin Disorder Drug Study
finance.yahoo.com - September 14 at 5:49 PM
finance.yahoo.com logoCelldex Announces Initiation of CDX-0159 Subcutaneous Formulation Study
finance.yahoo.com - September 13 at 5:24 PM
nasdaq.com logoCelldex Therapeutics Inc. Shares Approach 52-Week High - Market Mover
nasdaq.com - August 28 at 2:09 AM
nasdaq.com logoCelldex Therapeutics Inc. Shares Close in on 52-Week High - Market Mover
nasdaq.com - August 27 at 4:04 AM
nasdaq.com logoNotable Friday Option Activity: CLDX, AAL, ITCI
nasdaq.com - August 20 at 10:50 PM
finance.yahoo.com logoCelldex Therapeutics (CLDX) Reports Q2 Loss, Tops Revenue Estimates
finance.yahoo.com - August 6 at 12:12 AM
finance.yahoo.com logoCelldex Reports Second Quarter 2021 Financial Results and Provides Corporate Update
finance.yahoo.com - August 5 at 7:11 PM
finance.yahoo.com logoWill Celldex Therapeutics (CLDX) Report Negative Q2 Earnings? What You Should Know
finance.yahoo.com - July 29 at 6:38 PM
fool.com logoHow Good Were Celldex Therapeutics' Latest Clinical Results?
fool.com - July 24 at 7:46 AM
finance.yahoo.com logoWhat Is The Ownership Structure Like For Celldex Therapeutics, Inc. (NASDAQ:CLDX)?
finance.yahoo.com - July 18 at 12:22 PM
finance.yahoo.com logoCelldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - July 16 at 8:15 PM
nasdaq.com logoFirst Week of September 17th Options Trading For Celldex Therapeutics
nasdaq.com - July 16 at 3:14 PM
finance.yahoo.com logoCelldex (CLDX) Up Almost 40% Since Skin Disorder Study Data
finance.yahoo.com - July 14 at 1:55 PM
feeds.benzinga.com logoCelldex Therapeutics Raises $250M Via Equity To Support Development Of Skin Disease Candidate
feeds.benzinga.com - July 14 at 7:06 AM
finance.yahoo.com logoCelldex Therapeutics Announces Pricing of Upsized $250 Million Public Offering of Common Stock
finance.yahoo.com - July 13 at 10:54 PM
fool.com logoWhy Celldex Therapeutics Stock Is Jumping Again Today
fool.com - July 13 at 4:03 PM
finance.yahoo.com logoWhy Celldex Therapeutics Stock Is Skyrocketing Today
finance.yahoo.com - July 12 at 3:24 PM
finance.yahoo.com logoCelldex Therapeutics Stock Rocketed Above A Profit-Taking Zone — Here's Why
finance.yahoo.com - July 12 at 3:24 PM
finance.yahoo.com logoPremarket Movers Monday: Virgin Galactic, Apple, Sgoco, Celldex
finance.yahoo.com - July 12 at 9:27 AM
finance.yahoo.com logoCelldex Stock Surges As It Touts Early-Stage Skin Disease Study Win For CDX-0159
finance.yahoo.com - July 12 at 9:27 AM
finance.yahoo.com logoCelldex's stock jumps on positive data from early-stage, open-label clinical trial for hives treatments
finance.yahoo.com - July 12 at 9:27 AM
marketwatch.com logoCelldex Therapeutics Presents Positive Data from CDX-0159 Phase 1b Study in Chronic Inducible Urticaria at EAACI 2021 - MarketWatch
marketwatch.com - July 10 at 7:47 PM
finance.yahoo.com logoCelldex Therapeutics Presents Positive Data from CDX-0159 Phase 1b Study in Chronic Inducible Urticaria at EAACI 2021
finance.yahoo.com - July 9 at 6:32 PM
ca.finance.yahoo.com logoCLDX Jul 2021 25.000 put
ca.finance.yahoo.com - June 22 at 7:58 AM
ca.finance.yahoo.com logoCLDX Jul 2021 27.000 call
ca.finance.yahoo.com - June 22 at 7:58 AM
ca.finance.yahoo.com logoCLDX Jan 2022 25.000 call
ca.finance.yahoo.com - June 17 at 9:13 AM
ca.finance.yahoo.com logoCLDX Jan 2022 17.000 put
ca.finance.yahoo.com - June 16 at 11:57 PM
finance.yahoo.com logoCelldex Presents Preliminary Data from Ongoing CDX-527 Phase 1 Dose Escalation Trial at the 2021 ASCO Annual Meeting
finance.yahoo.com - June 4 at 9:38 AM
finance.yahoo.com logoCelldex Announces Acceptance of Abstract for CDX-0159 Phase 1b Results in Inducible Urticaria for Late-Breaking Presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2021
finance.yahoo.com - June 1 at 7:52 AM
finance.yahoo.com logoCelldex to Present at the Jefferies 2021 Virtual Healthcare Conference
finance.yahoo.com - May 26 at 6:12 PM
finance.yahoo.com logoWe Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth
finance.yahoo.com - May 13 at 9:32 AM
finance.yahoo.com logoCelldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates
finance.yahoo.com - May 6 at 9:25 PM
finance.yahoo.com logoCelldex Reports First Quarter 2021 Financial Results and Provides Corporate Update
finance.yahoo.com - May 6 at 4:25 PM
Get Celldex Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CLDX and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 12/1/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.